Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

ABSTRACT: REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with select advance, previously treated, Mismatch Repair-Proficient/Microsatellite (pMMR/MSS) stable solid cancers. The multi-cohort design will allow for the examination of 8 separate cohorts of different cancers to determine whether further examination may be warranted in the individual indications.

DISEASE(S): Neuroendocrine Tumors,Castrate Resistant Prostate Cancer,Carcinoma,Sarcoma,Small Cell Lung Carcinoma,Advanced Solid Tumors,Soft Tissue Sarcoma,Gastroenteropancreatic Neuroendocrine Neoplasm,Mesothelioma,Malignant Pleural Mesothelioma,Neuroendocrine Carcinoma Of Prostate,Anal Squamous Cell Carcinoma,Neoplasms,Prostatic Neoplasms,Carcinoma, Neuroendocrine,Colorectal Neoplasms,Mesothelioma, Malignant

PROVIDER: 2751562 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR